Admin, Author at Halberd Corporation

About Admin

This author has not yet filled in any details.
So far Admin has created 165 blog entries.

Sep 6 2023

Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)

By Admin|2023-09-06T05:46:15-04:00September 6th, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Anecdotal Results of Halberd’s Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers Jackson Center, PA September 6, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd’s patent-pending nasal spray to mitigate ...

Aug 22 2023

Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)

By Admin|2023-08-21T18:31:47-04:00August 22nd, 2023|Featured, Investor News, News, Press Releases|0 Comments

Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product Jackson Center, PA August 22, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model ...

Aug 14 2023

Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses

By Admin|2023-08-13T19:31:35-04:00August 14th, 2023|Featured, Investor News, News|0 Comments

Scientific Paper Presented at Research Symposium Jackson Center, PA August 14, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University (MSU). MSU students, Jourdan, L.K., Broadaway, S. Cassen, et. al. authored and presented a paper on this project at the recent Mississippi ...

Jul 20 2023

Halberd Corporation 2Q23 CEO Letter

By Admin|2023-07-19T20:54:59-04:00July 20th, 2023|Featured, Investor News, Update Letter|0 Comments

Jackson Center, PA, July 20, 2023 -- Halberd Corporation (OTC: HALB). During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to-treat diseases. 2nd QUARTER 2023 ACHIEVEMENTS Mississippi State University (MSU) is well on their way in ...

May 31 2023

Halberd CEO Mid-Quarter Update

By Admin|2023-05-31T05:53:16-04:00May 31st, 2023|Investor News, News, Press Releases, Uncategorized, Update Letter|0 Comments

Jackson Center, PA May 31, 2023 – Halberd Corporation (OTC-PINK: "HALB”) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts. Mississippi State University (MSU) has completed the impacts and sample collection for ...

May 23 2023

Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete

By Admin|2023-05-22T20:43:29-04:00May 23rd, 2023|Featured, Investor News, Press Releases|0 Comments

MSU is ahead of schedule and continues testing program Jackson Center, PA May 23, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray. The nasal spray is designed to eliminate ...

May 9 2023

Halberd Pre-Clinical Test Protocol Approved

By Admin|2023-05-08T18:54:10-04:00May 9th, 2023|Investor News, News, Press Releases|0 Comments

Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month End Jackson Center, PA May 9, 2023 – Halberd Corporation (OTC-PINK: "HALB”) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering ...

May 2 2023

Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma

By Admin|2023-05-01T20:26:07-04:00May 2nd, 2023|Investor News, Medical, News, Press Releases|0 Comments

Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process Jackson Center, PA May 2, 2023 – Halberd Corporation (OTC-PINK: "HALB”) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of ...

Apr 25 2023

Halberd Corporation 1Q23 CEO Letter

By Admin|2023-04-24T20:53:26-04:00April 25th, 2023|Investor News, News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application ...

Apr 20 2023

$HALB CEO, CTO and #YSU’s Dr. Sturrus Discuss CDC, Research Discoveries etc., on “The Street Reports Podcasts” Listen Now!

By Admin|2023-04-19T17:57:22-04:00April 20th, 2023|Featured, Investor News, News, Uncategorized|0 Comments

Jackson Center, PA, April 20, 2023 – Halberd Corporation’s (OTC-PINK: "HALB") President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on “The Street Reports” to discuss the company’s latest research discoveries and progress on eradicating CDC (Centers for ...

Previous 234 Next

jborza

About Admin